scholarly journals STUDI RETROSPEKTIF PENGGUNAAN TRIHEXYFENIDIL PADA PASIEN SKIZOFRENIA RAWAT INAP YANG MENDAPAT TERAPI ANTIPSKOTIK DI RUMAH SAKIT JIWA SAMBANG LIHUM

2016 ◽  
Vol 2 (2) ◽  
pp. 124-131
Author(s):  
Anggie Rahaya ◽  
Noor Cahaya
Keyword(s):  
Side Effects ◽  
Medical Records ◽  
Schizophrenia Patient ◽  
Univariate Analysis ◽  
Key Words Schizophrenia ◽  
Muscle Stiffness ◽  
Antipsychotic Treatment ◽  
Antipsychotic Therapy ◽  
Extrapyramidal Syndrome ◽  
Beneficial Effects

Trihexyphenidyl (THP) is used to treat symptoms of Parkinson's disease or involuntary movements due to the side effects of certain psychiatric drugs. It can also decrease other side effects such as muscle stiffness/rigidity (extrapyramidal syndrome or EPS). EPS were an unavoidable consequence of effective antipsychotic therapy. EPS reduce beneficial effects of antipsychotic treatment on the negative, cognitive, and mood symptom domains, while increasing the risk of tardive dyskinesia and reducing compliance. The purpose of this research was to analyze the percentage use of THP and the pattern of THP usage on schizophrenia patient which treated at Sambang Lihum Hospital. This retrospective observational study was conducted at an inpatient Sambang Lihum Hospital. This research were conducted to 264 medical records of patients period January 2013 to December 2013 which receive antipsychotics medication. Data were analyzed by univariate analysis. The result showed 94.32% (n=264) received THP. This research has shown the pattern of THP usage in Sambang Lihum Hospital which was to give THP directly to patients without EPS examination is 96.79% (n=249) and there are 15.66% (n=249) patients evaluated after 14 days after THP administered. Key Words: Schizophrenia, Trihexyphenidyl, EPS

scholarly journals Abnormalities in Glucose Blood Level during Antipsychotic Treatment in Schizophrenia Patients

2021 ◽  
Vol 9 (T3) ◽  
pp. 340-344
Author(s):  
Faisal Idrus ◽  
Theodorus Singara ◽  
Dwiwahyu Sunarto ◽  
Saidah Syamsuddin ◽  
Sonny T. Lisal
Keyword(s):  
Side Effects ◽  
Blood Sugar ◽  
Blood Sugar Level ◽  
Fasting Blood Glucose ◽  
Antipsychotic Treatment ◽  
Antipsychotic Therapy ◽  
Potential Health ◽  
Sugar Levels ◽  
Risperidone Group ◽  
Haloperidol Group

Background: Schizophrenia is one of the mental disorder with many problematic issues, in both psychologically and socially. This disease requires provision of long-term antipsychotic therapy, hence could rise other potential health problems. Antipsychotic treatment can cause serious glucometabolic side-effects, including type 2 diabetes and hyperglycemic emergency. Recent attention has also been focused on antipsychotic-induced hyperglycemic emergencies experienced by new users of typical and atypical antipsychotic. Patients treated with atypical APDs have ~10 times higher risk in developing hyperglycaemic emergencies. In our pre-eliminary study, hyperglycemia condition in new patients occurs in four  in seven patients who received typical and atypical antipsychotics. This condition is often overlooked and is not routinely evaluated. Moreover, it can develop into diabetes and increase the risk of morbidity and mortality in schizophrenia patients. In this study, we would like to determine the acute effects of metabolic (hyperglycemia) in patients treated with antipsychotic (Risperidone and Haloperidol) Measurement of blood sugar levels was performed in groups treated with haloperidol (N = 15) and treated with risperidone (N = 15). Plasma samples were taken at the beginning of treatment, in week IV, and in week VIII. The measurement of glucose levels was performed after meal and in early morning before breakfast (fasting blood glucose level 8 hours). Results: The blood sugar level after meals was significantly higher in the Risperidone group compared to the Haloperidol group  (p <0.001) after IV and VIII weeks. Meanwhile, the fasting blood sugar level was significantly higher in the Risperidone group compared to the Haloperidol group after VIII weeks of treatment ( p <0.001). Conclusions: Both antipsychotics can cause an increase in blood sugar levels. Treatment with Risperidone significantly increased the blood sugar levels compared to treatment with haloperidol. Measurement of blood sugar level is needed to monitor the metabolic effect of antipsychotic, especially in patients treated with Risperidone. It is necessary to have dietary regulation and physical activities to prevent undesired metabolic side effects.

scholarly journals The Changes of Electrocardiogram in Neuroleptic Cardiomyopathy

2018 ◽  
Vol 3 (7) ◽  
Keyword(s):  
Side Effects ◽  
Medical Records ◽  
Early Diagnostics ◽  
Antipsychotic Therapy ◽  
Cardiac Pathology ◽  
Group Iii ◽  
Latent Stage ◽  
Clinical Stages ◽  
Group Ii

The data of medical records of 81 patients with schizophrenia who died (men – 58, women – 23) were retrospectively studied, almost two thirds of them were aged from 41 to 60 years. Three groups of observations were identified: group me (comparison) – 12 patients receiving antipsychotic therapy, but did not have a cardiac pathology; group II – 44 patients with NCH in the latent stage; group III – 25 patients with manifesting disease (developed and terminal clinical stages). 406 electrocardiograms were analyzed in groups 53, 282 and 71, respectively. Eight most common electrocardiographic signs are considered. Dynamics of certain characteristics was shown to be of value for early diagnostics of neuroleptic cardio toxic side effects.

Functional morphology of gonads under conditions of antipsychotic therapy

2014 ◽  
Vol 60 (4) ◽  
pp. 30-34
Author(s):  
B P Volkov
Keyword(s):  
Side Effects ◽  
Functional Morphology ◽  
Antipsychotic Agents ◽  
Antipsychotic Treatment ◽  
Hormonal Activity ◽  
Antipsychotic Therapy ◽  
Functional Disturbances ◽  
Neuroleptic Therapy

Gonadotoxic side effects of antipsychotic agents are known to cause serious disturbances in both germinative and endocrine testicular functions. The hormonal activity of the testes undergo undulating changes whereas the germinative function progressively decreases from the onset of neuroleptic therapy. The morphological and functional disturbances in the testicles are especially well pronounced after 10 years of antipsychotic treatment. The morphofunctional changes in the ovaries become apparent from the very beginning of antipsychotropic therapy; they are indicative of the progressive impairment of reproductive and endocrine functions of the female gonads.

scholarly journals Incidence of Orthostatic Hypotension in Schizophrenic Patients Using Antipsychotics at Sambang Lihum Mental Health Hospital, South Kalimantan

2021 ◽  
Vol 4 (3) ◽  
pp. 210-218
Author(s):  
Noor Cahaya ◽  
Sandra Putri Wijaya ◽  
Khoerul Anwar
Keyword(s):  
Mental Health ◽  
Side Effects ◽  
Orthostatic Hypotension ◽  
Medical Records ◽  
Univariate Analysis ◽  
Data Sampling ◽  
Number Of Patients ◽  
Schizophrenic Patients ◽  
Mental Health Hospital ◽  
Health Hospital

Schizophrenia is a psychiatric disorder that requires antipsychotics therapy. Antipsychotics cause many side effects, including orthostatic hypotension. The study aimed to describe the incidence of orthostatic hypotensive side effects experiences by schizophrenia patients at the Sambang Lihum Mental Health Hospital, South Kalimantan. This research was observational description research with data sampling by medical records. This research was conducted to 300 medical records of patients period January-December 2018 which received antipsychotics medication and data analyzed by univariate analysis. The results showed the number of patients who experienced orthostatic hypotension was 98 patients (32.67%) and no experienced were 202 patients (67.33%). Incidence of orthostatic hypotension in haloperidol 54.35% (N=46); trifluoperazine 100% (N=1); clozapine 84.62% (N=13); olanzapine 100% (N=1); haloperidol-chlorpromazine 27.27% (N=11); haloperidol-haloperidol 42.86% (N=7); clozapine-risperidone 16.67% (N=6); haloperidol-clozapine 15.05% (N=93); haloperidol-olanzapine 50% (N=2); haloperidol-risperidone 31.82% (N=22); trifluoperazine-olanzapine 100% (N=1); trifluoperazine-clozapine 22.22% (N=9); trifluoperazine-risperidone 5.56% (N=18); chlorpromazine-haloperidol-haloperidol 33.3% (N=3); chlorpromazine-haloperidol-trifluoperazine 100% (N=3); haloperidol-trifluoperazine-chlorpromazine 100% (N=1); chlorpromazine-haloperidol-clozapine 42.86% (N=7); chlorpromazine-trifluoperazine-clozapine 100% (N=1); chlorpromazine-trifluoperazine-olanzapine 100% (N=1); chlorpromazine-trifluoperazine-risperidone 50% (N=2); trifluoperazine-haloperidol-risperidone 100% (N=4); haloperidol-trifluoperazine-risperidone 100% (N=1); trifluoperazine-haloperidol-clozapine 40% (N=5); haloperidol-haloperidol-clozapine 80% (N=5); clozapine-risperidone-trifluoperazine 100% (N=4); risperidone-clozapine-haloperidol 20% (N=10). The conclusion from this study was the percentage of orthostatic hypotension on schizophrenia patients at the Sambang Lihum Mental Health Hospital was 32.67% (N=98).

scholarly journals Karakteristik Pasien Dengan Ektrapiramidal Sindrom Di Bangsal Jiwa RSUD Banyumas

2021 ◽  
Vol 6 (2) ◽  
pp. 106
Author(s):  
Sugiarto Sugiarto ◽  
Mustiah Yulistiani
Keyword(s):  
Side Effects ◽  
Junior High School ◽  
Univariate Analysis ◽  
Extrapyramidal Syndrome ◽  
Medical Diagnoses ◽  
Descriptive Research ◽  
Frequent Relapses ◽  
Extrapyramidal Syndromes ◽  
History Of ◽  
First Time

The provision of antipsychotics can cause poot response and side effects such symptoms of extrapyramidal metabolic syndrome. Extrampyramidal side effects are one of the causes of patients become frequent relapses and treatment will be even longer and can last a lifetime. Objective know the description of the characteristics on the patients with extrapyramidal syndrome. This research uses non-experimental research and descriptive research type. The sample is 30 patients with total sampling. The instrument with questionnaire sheets. Univariate analysis with descriptive frequencies was used to analyze the data obtained. Result the most respondents, 13 respondents (43,3%), had extrapyramidal syndromes, 13 respondents (43,3%) were aged 17-25 years old, 21 respondents (70,0%) were male, 10 respondents (33,3%) were graduates from junior high school. Most patients 11 respondents (36,7%), received the therapy for chlorpromazine + tribexyphenidyl + haloperidol, 13 respondents (43,3%) received the therapy for schizoaffective medical diagnoses, 17 respondents (56,7%) had a history of irregular therapy, 26 respondents (86,7%) did not have history of comorbidities and 12 respondents (40,0%) had a history of early mental illness for the first time. Most EPS patients got chlorpromazine, had a history of irregular therapy, had no history of comorbidities and had a history of early mental disorder for first time.   Keywords: extrapyramidal syndrome

Antipsychotic-induced supersensitivity – A reappraisal

2021 ◽  
pp. 000486742110256
Author(s):  
William Lugg
Keyword(s):  
Tardive Dyskinesia ◽  
Significant Proportion ◽  
Underlying Mechanism ◽  
Antipsychotic Treatment ◽  
Physiological Changes ◽  
Antipsychotic Therapy ◽  
Neurotransmitter Systems ◽  
Potential Benefits ◽  
Treatment Refractory ◽  
Brain Pathways

Objectives: Tardive dyskinesia, psychotic relapse and treatment-refractory psychosis have long been associated. A common underlying mechanism involving antipsychotic-induced ‘supersensitivity’, albeit in different brain pathways, was proposed as early as 1978. This piece seeks to reappraise the concept and potential implications of antipsychotic-induced supersensitivity. Conclusions: Evidence increasingly suggests that chronic antipsychotic exposure induces neuroadaptive physiological changes in dopaminergic, and other, neurotransmitter systems that may render some individuals more vulnerable to psychotic relapse - including those receiving continuous antipsychotic treatment. It is possible that in treating every episode of psychosis with prolonged or indefinite antipsychotic therapy, we paradoxically increase the risk of psychotic relapse in a significant proportion of people. A greater appreciation of supersensitivity may allow us to optimise any potential benefits of antipsychotics while minimising the risk of inadvertent iatrogenic harms. More research is needed to improve our understanding of the underlying neurophysiology of supersensitivity and to better identify which individuals are most vulnerable to its development. It is time we paid more attention to the concept, emerging evidence and potential implications of antipsychotic-induced supersensitivity and, where appropriate, adjusted our practice accordingly.

scholarly journals Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists

Cells ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 185
Author(s):  
Clara Depommier ◽  
Rosa Maria Vitale ◽  
Fabio Arturo Iannotti ◽  
Cristoforo Silvestri ◽  
Nicolas Flamand ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Univariate Analysis ◽  
Metabolic Effects ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Akkermansia Muciniphila ◽  
Beneficial Effects ◽  
Daily Ingestion ◽  
Before And After ◽  
Palmitoyl Glycerol

Akkermansia muciniphila is considered as one of the next-generation beneficial bacteria in the context of obesity and associated metabolic disorders. Although a first proof-of-concept of its beneficial effects has been established in the context of metabolic syndrome in humans, mechanisms are not yet fully understood. This study aimed at deciphering whether the bacterium exerts its beneficial properties through the modulation of the endocannabinoidome (eCBome). Circulating levels of 25 endogenous endocannabinoid-related lipids were quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in the plasma of overweight or obese individuals before and after a 3 months intervention consisting of the daily ingestion of either alive or pasteurized A. muciniphila. Results from multivariate analyses suggested that the beneficial effects of A. muciniphila were not linked to an overall modification of the eCBome. However, subsequent univariate analysis showed that the decrease in 1-Palmitoyl-glycerol (1-PG) and 2-Palmitoyl-glycerol (2-PG), two eCBome lipids, observed in the placebo group was significantly counteracted by the alive bacterium, and to a lower extent by the pasteurized form. We also discovered that 1- and 2-PG are endogenous activators of peroxisome proliferator-activated receptor alpha (PPARα). We hypothesize that PPARα activation by mono-palmitoyl-glycerols may underlie part of the beneficial metabolic effects induced by A. muciniphila in human metabolic syndrome.

Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats

2021 ◽  
Vol 35 (3) ◽  
pp. 284-302
Author(s):  
Ilijana Babic ◽  
Dominic Sellers ◽  
Paul L Else ◽  
Jessica Nealon ◽  
Ashleigh L Osborne ◽  
...  
Keyword(s):  
Side Effects ◽  
Chronic Treatment ◽  
Antipsychotic Treatment ◽  
Metabolic Markers ◽  
Metabolic Side Effects ◽  
Feeding Efficiency ◽  
Adaptive Mechanisms ◽  
Liver And Kidney ◽  
Glucagon Like Peptide 1 ◽  
Peripheral Markers

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that prevents metabolic side effects of the antipsychotic drugs (APDs) olanzapine and clozapine through unknown mechanisms. Aim: This study aimed to investigate the effect of chronic APD and liraglutide co-treatment on key neural and peripheral metabolic signals, and acute liraglutide co-treatment on clozapine-induced hyperglycaemia. Methods: In study 1, rats were administered olanzapine (2 mg/kg), clozapine (12 mg/kg), liraglutide (0.2 mg/kg), olanzapine + liraglutide co-treatment, clozapine + liraglutide co-treatment or vehicle for six weeks. Feeding efficiency was examined weekly. Examination of brain tissue (dorsal vagal complex (DVC) and mediobasal hypothalamus (MBH)), plasma metabolic hormones and peripheral (liver and kidney) cellular metabolism and oxidative stress was conducted. In study 2, rats were administered a single dose of clozapine (12 mg/kg), liraglutide (0.4 mg/kg), clozapine + liraglutide co-treatment or vehicle. Glucose tolerance and plasma hormone levels were assessed. Results: Liraglutide co-treatment prevented the time-dependent increase in feeding efficiency caused by olanzapine, which plateaued by six weeks. There was no effect of chronic treatment on melanocortinergic, GABAergic, glutamatergic or endocannabionoid markers in the MBH or DVC. Peripheral hormones and cellular metabolic markers were unaltered by chronic APD treatment. Acute liraglutide co-treatment was unable to prevent clozapine-induced hyperglycaemia, but it did alter catecholamine levels. Conclusion: The unexpected lack of change to central and peripheral markers following chronic treatment, despite the presence of weight gain, may reflect adaptive mechanisms. Further studies examining alterations across different time points are required to continue to elucidate the mechanisms underlying the benefits of liraglutide on APD-induced metabolic side effects.

scholarly journals Ulipristal Acetate in Myomectomy Optimization in an Infertile Patient with Giant Myomas

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Elena de la Fuente ◽  
María Dolores Borrás ◽  
Miriam Rubio ◽  
Nuria Abril
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Normal Pregnancy ◽  
Uterine Wall ◽  
Surgical Removal ◽  
Preoperative Treatment ◽  
Ulipristal Acetate ◽  
Infertile Patient ◽  
Beneficial Effects ◽  
Pregnancy And Delivery

The use of ulipristal acetate (UPA) has been recently introduced in the treatment of uterine leiomyomas. This drug has proven useful to control menometrorrhagia and to reduce myoma size. In the case presented here, we show the benefits of UPA treatment in facilitating surgical removal of giant myomas in an infertile patient. In addition to myoma reduction and a better control of preoperative bleeding, the treatment with UPA reduced the duration and complexity of the surgery, as well as the area of uterine wall involved and the resulting scar. No side effects were observed and the patient became pregnant 6 months after the surgery and had a normal pregnancy and delivery. This case report shows the beneficial effects of UPA in the preoperative treatment of myomas which affect uterus function.

Omentin-1 attenuates glucocorticoid-induced cardiac injury by phosphorylating GSK3β

2021 ◽  
Vol 66 (4) ◽  
pp. 273-283
Author(s):  
Zhousheng Jin ◽  
Fangfang Xia ◽  
Jiaojiao Dong ◽  
Tingting Lin ◽  
Yaoyao Cai ◽  
...  
Keyword(s):  
Side Effects ◽  
Cardiac Hypertrophy ◽  
Cardiac Injury ◽  
Experimental Studies ◽  
Chronic Administration ◽  
Cardiovascular Complications ◽  
Rat Serum ◽  
Cardiac Side Effects ◽  
Beneficial Effects

Glucocorticoid excess often causes a variety of cardiovascular complications, including hypertension, atherosclerosis, and cardiac hypertrophy. To abrogate its cardiac side effects, it is necessary to fully disclose the pathophysiological role of glucocorticoid in cardiac remodelling. Previous clinical and experimental studies have found that omentin-1, one of the adipokines, has beneficial effects in cardiovascular diseases, and is closely associated with metabolic disorders. However, there is no evidence to address the potential role of omentin-1 in glucocorticoid excess-induced cardiac injuries. To uncover the links, the present study utilized rat model with glucocorticoid-induced cardiac injuries and clinical patients with abnormal cardiac function. Chronic administration of glucocorticoid excess reduced rat serum omentin-1 concentration, which closely correlated with cardiac functional parameters. Intravenous administration of adeno-associated virus encoding omentin-1 upregulated the circulating omentin-1 level and attenuated glucocorticoid excess-induced cardiac hypertrophy and functional disorders. Overexpression of omentin-1 also improved cardiac mitochondrial function, including the reduction of lipid deposits, induction of mitochondrial biogenesis, and enhanced mitochondrial activities. Mechanistically, omentin-1 phosphorylated and activated the GSK3β pathway in the heart. From a study of 28 patients with Cushing’s syndrome and 23 healthy subjects, the plasma level of glucocorticoid was negatively correlated with omentin-1, and was positively associated with cardiac ejection fraction and fractional shortening. Collectively, the present study provided a novel role of omentin-1 in glucocorticoid excess-induced cardiac injuries and found that the omentin-1/GSK3β pathway was a potential therapeutic target in combating the side effects of glucocorticoid.

Sign in / Sign up

Export Citation Format

Share Document